Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646087 | 0.95 | KIF11 (0.48) | KIF11KCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL10192147 | 0.89 | KIF11 (0.50) | KIF11KCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL13309006 | 0.89 | KIF11 (0.50) | KIF11KCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL6469068 | 0.86 | IDO1 (0.38) | KDM4EALDH1A1HPGDHTTMEN1 | |
| SCHEMBL644374 | 0.84 | KIF11 (0.58) | KIF11KCNH2LMNAMAPK8MAPK9 | |
| SCHEMBL6021536 | 0.83 | KIF11 (0.51) | KIF11KCNH2KDM4EMEN1KMT2A | |
| SCHEMBL644778 | 0.82 | KIF11 (0.55) | KIF11KCNH2KDM4EMEN1KMT2A | |
| SCHEMBL13309219 | 0.82 | KIF11 (0.51) | KIF11KCNH2KDM4EMEN1KMT2A | |
| SCHEMBL6467220 | 0.81 | KIF11 (0.54) | KIF11KCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL3271196 | 0.81 | KIF11 (0.58) | KIF11KCNH2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7629477-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050165089-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-28 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | KIF11 525/4885KCNH2 3954/4885KDM4E 2220/4885 |
| US-20050165089-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885KDM4E 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.